글로벌 연구동향
방사선종양학
- 2017년 03월호
[Radiotherapy and Oncology] A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer성균관의대 / 이지윤, 선종무, 박근칠 *
- 출처
- Radiotherapy and Oncology
- 등재일
- February 2017
- 저널이슈번호
- Volume 122, Issue 2, Pages 217–223
- 내용
Abstract
Purpose
Although concurrent chemoradiotherapy (CCRT) is the standard of care for locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN), the optimal CCRT regimen is not yet defined. We conducted a phase II study of weekly docetaxel and cisplatin treatment with concurrent radiotherapy (RT) to investigate the efficacy and toxicity profiles.
Material and methods
Forty-one patients with locally advanced SCCHN were treated with 20 mg/m2 docetaxel plus 20 mg/m2 cisplatin weekly for 6 cycles, concurrent with RT, between April 2010 and March 2013.
Results
The mean total doses of docetaxel and cisplatin were 109.3 mg/m2 and 110.7 mg/m2, respectively. The mean total delivered dose of radiation was 67.7 Gy. Thirty-seven patients (90.3%) received 5 or more cycles of treatment. At the 1-month post-CCRT tumor response evaluation, 13 patients (39.9%) achieved a complete response (CR) [95% confidence interval (95% CI), 20.1–56.6]. Thirty-two patients (78.0%) ultimately achieved CR during the post-treatment follow-up period. With a median follow-up of 3.4 years, the 2-year overall survival (OS), disease-free survival (DFS), and distant disease-free survival (DDFS) were 85.4% (95% CI, 74.6–96.2%), 72.8% (95% CI, 59.2–86.4%), and 82.4% (95% CI, 70.7–94.1%), respectively. Overall, grade 3 toxicities occurred in 21 patients (51.2%), most commonly mucositis (39.0%), neutropenia (9.8%), or dysphagia (4.9%). A grade 4 adverse event was observed in only one patient with neutropenia.
Conclusions
CCRT with weekly docetaxel and cisplatin shows promising antitumor activity with manageable toxicity profiles for patients with locally advanced SCCHN.
Author information
Ji Yun Lee a,1, Jong-Mu Sun a,1, Dongryul Oh b, Sung Hee Lim a, Sangah Chi c, Se-Hoon Lee a, Sin-Ho Jung c, Myung-Ju Ahn a, Yong Chan Ahn b, Keunchil Park a,⇑
aDepartment of Medicine; bDepartment of Radiation Oncology; and cDepartment of Biostatistics and Bioinformatics, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- 키워드
- Head and neck cancer, Concurrent chemoradiotherapy, Efficacy, Toxicity, Quality of life
- 덧글달기
- 이전글 [Radiother Oncol. ] Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis.
- 다음글 [Liver Int.] Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area.